Literature DB >> 22842504

Graves' hyperthyroidism-induced psychosis treated with aripiprazole--a case report.

Livia R Macedo1, Jehan Marino, Brady Bradshaw, Joseph Henry.   

Abstract

Graves' disease is an autoimmune syndrome with symptoms such as tachycardia, atrial fibrillation, and psychiatric symptoms. Limited evidence exists for the treatment of Graves' hyperthyroidism-induced psychosis with atypical antipsychotics. A 47-year-old female with a psychiatric history of bipolar disorder presented for the first time to the psychiatric hospital. She was agitated and grossly psychotic with delusions. Electrocardiogram showed atrial fibrillation and tachycardia. Drug screen urinalysis was negative. Endocrine workup resulted in a diagnosis of Graves' disease (thyroid-stimulating hormone [TSH]: 0.005 μIU/mL, triiodothyronine [T3]: 537 ng/dL, thyroxine [T4]: 24 mcg/dL, free T4: 4.5 ng/dL, positive antithyroid peroxidase antibody, and antinuclear antibody). Aripiprazole 10 mg daily was initiated and titrated to 15 mg daily on day 4. On day 16, her suspicious behavior, judgment, and insight improved. Other medications given included aspirin 325 mg daily, metoprolol 25 mg twice daily, titrated to 12.5 mg twice daily, and methimazole 30 mg daily, titrated to 20 mg twice daily, and discontinued on day 29. The patient received radioiodine I-131 treatment 1 week later. We report the first known case on the use of aripriprazole to treat Graves' hyperthyroidism-induced psychosis. Further studies examining the long-term effects and appropriate dose and duration of aripiprazole in this patient population are needed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22842504     DOI: 10.1177/0897190012451934

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  1 in total

1.  Hyperthyroidism Presenting With Mania and Psychosis: A Case Report.

Authors:  Haris Asif; Ifediba Nwachukwu; Arshan Khan; Giovanna Rodriguez; Gul Bahtiyar
Journal:  Cureus       Date:  2022-02-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.